IL6 and cancer: Taken together, our study provides the impetus to discover new strategies, for instance, the development of efficient agents, including JAK2/STAT3 inhibitors and humanized monoclonal antibodies against IL6 to re-sensitize resistant NPC cells or other cancers that were resistant to chemotherapy.